Piramal Pharma Limited's overseas subsidiary, Piramal Critical Care Inc., has entered into a strategic collaboration with Blue-Zone Technologies Ltd. to develop comprehensive technology for capturing and recycling waste anaesthetic gases. The partnership, announced on 5th February 2026, aims to address environmental concerns while ensuring continued availability of essential anaesthetic products for medical procedures worldwide.

Strategic Partnership Overview

The collaboration combines Blue-Zone's innovative waste anaesthesia gas capture technology with Piramal's established global manufacturing and marketing infrastructure. This partnership specifically targets the environmental impact of volatile anaesthetics while maintaining their critical role in healthcare delivery.

Implementation Strategy

Pending regulatory approval in Europe, Blue-Zone will offer its Phoenix Deltasorb® waste anaesthetic gas capture systems to PCC's customers in France and Germany initially. Under the agreement, Blue-Zone will handle all activities related to the supply and deployment of its systems in healthcare facilities, while PCC will process the captured waste anaesthetic gas using Blue-Zone's technology to produce Sevoflurane USP for human use in Canada.

Leadership Perspective

Jeff Hampton, President and COO of Piramal Critical Care, emphasized the partnership's significance in balancing clinical needs with environmental responsibility. He stated that the collaboration enables hospitals to select inhaled anaesthetics based on clinical requirements while supporting sustainable healthcare objectives. Hampton highlighted Piramal's commitment to ensuring patients receive critical care while advancing environmentally responsible anaesthesia approaches.

Company Profiles

Piramal Critical Care operates as a global leader in anaesthesia, pain management and intrathecal therapy, serving hospitals in more than 100 countries worldwide. The company maintains manufacturing facilities in Bethlehem, PA, United States, Digwal, India, and Dahej, India, all operating under strict GMP regulations with global regulatory accreditations.

Blue-Zone Technologies, based in Ontario, Canada, specializes in cleantech pharma solutions focused on waste anaesthetic gas capture, recovery, and processing. The company develops and markets equipment and processes for the complete lifecycle of volatile anaesthetics, supporting both environmental protection and anaesthetic drug production.

Future Expansion Plans

Both companies anticipate expanding the scope of waste anaesthetic gas capture, collection and recycling operations, along with the marketing of Sevoflurane USP produced from waste anaesthetic gas, into additional geographic markets beyond the initial European launch.

Piramal Pharma Limited has announced the completion of tenure of its Independent Director Mr. Subramanian Ramadorai, in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The disclosure was made to both BSE Limited and National Stock Exchange of India Limited on February 5, 2026.

Director Tenure Details

Mr. Subramanian Ramadorai, holding Director Identification Number (DIN) 00000002, will complete his term of 5 consecutive years as Independent Director on February 8, 2026. The company has informed that Mr. Ramadorai expressed his desire to retire from the Board in the interest of pursuing personal priorities.

Board Transition and Committee Restructuring

Effective February 9, 2026, Mr. Ramadorai will cease to be an Independent Director of the company and consequently step down as Chairman/Member of various Board Committees on which he served. The Board has undertaken re-constitution of the Committees in accordance with applicable regulatory requirements to ensure continued compliance.

Board's Acknowledgment

The Board of Directors has placed on record its heartfelt gratitude for the valuable insights and guidance received from Mr. Ramadorai during his tenure. The company has specifically clarified that there is no material reason for his cessation other than his personal decision to retire and pursue personal priorities.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI Listing Regulations, demonstrating the company's commitment to maintaining transparency with stakeholders. The announcement was signed by Company Secretary Tanya Sanish and communicated to both stock exchanges where the company's shares are listed.